From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
Retatrutide (LY3437943) is a triple agonist peptide of the glucagonreceptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-likepeptide-1receptor (GLP-1R). Retatrutide binds human GCGR, GIPR, and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide can be used for the research of obesity .
Retatrutide (LY3437943) TFA is a triple agonist peptide of the glucagonreceptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-likepeptide-1receptor (GLP-1R). Retatrutide TFA binds human GCGR, GIPR, and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide TFA can be used for the research of obesity .
Retatrutide (LY3437943) acetate is a triple agonist peptide of the glucagonreceptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-likepeptide-1receptor (GLP-1R). Retatrutide acetate inhibits human GCGR, GIPR, and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide acetate can be used for the research of obesity .
Des His1, Glu8 Exendin-4 is a potent glucagon-likepeptide-1receptor (GLP-1-R) antagonist. Des His1, Glu8 Exendin-4 improves glucose homeostasis by regulating both insulin secretion and glucose production. Des His1, Glu8 Exendin-4 can be used for the research of type 2 diabetic and gastrointestinal .
Semaglutide, a long-acting GLP-1 analogue, is a glucagon-likepeptide-1(GLP-1)receptor agonist. Semaglutide has the potential for type 2 diabetes treatment.
Albiglutide fragment (GLP-1 (7-36) analog) TFA is an active fragment of Albiglutide (7-36) and a glucagon-likepeptide-1 (GLP-1) analog (a long-acting GLP-1receptor agonist). Albiglutide is produced by the fusion of DPP-4 resistant GLP-1 dimer with the human albumin gene. Moreover, Albiglutide fragment TFA significantly reduces glycosylated hemoglobin (A1C) and is used in type 2 diabetes (T2D) studies .
Albiglutide fragment (GLP-1 (7-36) analog) is an active fragment of Albiglutide (7-36) and a glucagon-likepeptide-1 (GLP-1) analog (a long-acting GLP-1receptor agonist). Albiglutide is produced by the fusion of DPP-4 resistant GLP-1 dimer with the human albumin gene. Moreover, Albiglutide fragment significantly reduces glycosylated hemoglobin (A1C) and is used in type 2 diabetes (T2D) studies .
Semaglutide TFA, a long-acting GLP-1 analogue, is a glucagon-likepeptide-1(GLP-1)receptor agonist. Semaglutide TFA has the potential for type 2 diabetes treatment.
Pal-Glu(OSu)-OH is a side chain of Liraglutide. Liraglutide is a glucagon-likepeptide-1 (GLP-1) receptor agonist that can be used for type 2 diabetes mellitus research .
Dapiglutide (ZP7570) is a long-acting glucagon-likepeptide-1receptor 1R (GLP-1R)/Glucagon-likepeptide-2 receptor (GLP-2R) dual agonist. Dapiglutide can be used for short bowel syndrome (SBS) research .
Orforglipron (LY3502970) (Compound 67) is an orally active agonist for Glucagon-likepeptide-1receptor (GLP-1R), which exhibits potency in ameliorates the type 2 diabete .
Shanzhiside methy lester is isolated from lamiophlomis rotata. Shanzhiside methyl ester is a small molecule glucagon-likepeptide-1 (GLP-1) receptor agonist and has the ability to induce anti-allodynic tolerance .
Boc5 is a non-peptidic glucagon-likepeptide-1receptor agonist. Boc5 causes sustained glycemic control and weight loss in diabetic mice. Boc5 can be used in research of diabetic .
GLP-1 receptor agonist 14 (compound 73) is a potent agonist of glucagon-likepeptide-1 (GLP-1). GLP-1 receptor agonist 14 plays an important role in diabetes or other metabolic disorders .
TT-OAD2 free base is a non-peptideglucagon-likepeptide-1 (GLP-1) receptor agonist with an EC50 of 5 nM. TT-OAD2 free base has the potential for diabetes treatment .
V-0219 (Compound 9) is an orally active, positive allosteric modulator (PAM) of the glucagon-likepeptide-1receptor (GLP-1R). V-0219 can be used for obesity-associated diabetes research .
V-0219 hydrochloride (Compound 9) is an orally active, positive allosteric modulator (PAM) of the glucagon-likepeptide-1receptor (GLP-1R). V-0219 hydrochloride can be used for obesity-associated diabetes research .
Liraglutide- 13C6, 15N (TFA)is the 13C and 15N labeledLiraglutide(HY-P0014). Liraglutide is a glucagon-likepeptide-1 (GLP-1) receptor agonist used clinically to treat type 2 diabetes mellitus .
Liraglutide- 13C5, 15N (tetraTFA)is the 13C and 15N labeledLiraglutide(HY-P0014) . Liraglutide is a glucagon-likepeptide-1 (GLP-1) receptor agonist used clinically to treat type 2 diabetes mellitus .
Tirzepatide hydrochloride (LY3298176 hydrochloride) is a glucose-dependent insulin nutritive polypeptide (GIP) and glucagon-likepeptide-1(GLP-1)receptor dual agonist. Tirzepatide hydrochloride has neuroprotective effects and can be used in the study of type 2 diabetes, diabetes-related neuropathy and obesity .
Orforglipron hemicalcium hydrate (LY3502970 hemicalcium hydrate; GLP-1 receptor agonist 1 hemicalcium hydrate) is the calcium salt hydrate form of Orforglipron (HY-112185). Orforglipron is an orally active agonist for Glucagon-likepeptide-1receptor (GLP-1R), which exhibits potency in ameliorating the type 2 diabete .
GLP-1 receptor agonist 4 is a glucagon-likepeptide-1receptor (GLP-1R) agonist extracted from patent WO2009111700A2, compound 87, has an EC50 of 64.5 nM. GLP-1 receptor agonist 4 can be used in the research for treatment of diabetes .
Tirzepatide (LY3298176) is a glucose-dependent insulin nutritive polypeptide (GIP) and glucagon-likepeptide-1(GLP-1)receptor dual agonist. Tirzepatide has neuroprotective effects and can be used in the study of type 2 diabetes, diabetes-related neuropathy and obesity .
Tirzepatide TFA (LY3298176 hydrochloride) is a glucose-dependent insulin nutritive polypeptide (GIP) and glucagon-likepeptide-1(GLP-1)receptor dual agonist. Tirzepatide TFA has neuroprotective effects and can be used in the study of type 2 diabetes, diabetes-related neuropathy and obesity .
Bamadutide (SAR425899) is a potent dual glucagon-likepeptide-1receptor/glucagonreceptor agonist. Bamadutide (SAR425899) improves postprandial glucose control by significantly enhancing β-cell function and slowing glucose absorption rate in vivo. Bamadutide (SAR425899)can be used for type 2 diabetes research .
GLP-1 receptor agonist 7 is a potent agonist of glucagon-likepeptide-1 (GLP-1). GLP-1 receptor agonist 7 has the potential for the research of GLP-1-associated diseases, disorders, and conditions including diabetes mellitus (extracted from patent WO2021219019A1, compound 130b) .
Exendin-4 (3-39) is a peptide. Exendin-4 (3-39) is a truncated form of Exendin-4 (HY-13443) that lacks the first two amino acids. Exendin-4 is a potent Glucagon-likepeptide-1receptor (GLP-1r) agonist. Exendin-4 (3-39) and Exendin-4 can be used for the research of diabetic and hypothalamic-pituitary-adrenal (HPA) axis .
Taspoglutide is a long-acting glucagon-likepeptide 1 (GLP-1) receptor agonist developed for treatment of type 2 diabetes, with an EC50 value of 0.06 nM.
Ecnoglutide (XW003) is a long-acting, cAMP-biased glucagon-likepeptide 1(GLP-1) receptor agonist. Ecnoglutide can be used for research of T2DM and obesity .
GLP-1 moiety from Dulaglutide is a 31-amino acid fragment of Dulaglutide which is a glucagon-likepeptide 1receptor (GLP-1) agonist, extracted from patent US 20160369010 A1.
GLP-1R Antagonist 1 (compound 5d) is an orally active, CNS penetrant and non-competitive antagonist of glucagon-likepeptide 1receptor (GLP-1R), with an IC50 of 650 nM .
GLP-1(9-36)amide is a major metabolite of glucagon-likepeptide-1-(7-36) amide formed by the enzyme dipeptidyl peptidase-4 (DPP-4). GLP-1(9-36)amide acts as an antagonist to the human pancreatic GLP-1 receptor .
GLP-1(9-36)amide TFA is a major metabolite of glucagon-likepeptide-1-(7-36) amide formed by the enzyme dipeptidyl peptidase-4 (DPP-4). GLP-1(9-36)amide TFA acts as an antagonist to the human pancreatic GLP-1 receptor .
Mazdutide (IBI-362; LY-3305677) is a long-acting synthetic oxyntomodulin analog. Mazdutide is also a co-agonist of glucagon-likepeptide (GLP-1R) and glucagonreceptor (GCGR). Mazdutide binds human and mouse GCGR (Ki: 17.7 nM and 15.9 nM, respectively) and GLP-1R (Ki: 28.6 nM and 25.1 nM, respectively) and stimulates insulin secretion from mouse islets (EC50: 5.2 nM). Mazdutide is used in studies of obesity and type 2 diabetes (T2D) .
Mazdutide (IBI-362; LY-3305677) TFA is a long-acting synthetic oxyntomodulin analog. Mazdutide is also a co-agonist of glucagon-likepeptide (GLP-1R) and glucagonreceptor (GCGR). Mazdutide TFA binds human and mouse GCGR (Ki: 17.7 nM and 15.9 nM, respectively) and GLP-1R (Ki: 28.6 nM and 25.1 nM, respectively) and stimulates insulin secretion from mouse islets (EC50: 5.2 nM). Mazdutide TFA is used in studies of obesity and type 2 diabetes (T2D) .
Retatrutide (LY3437943) is a triple agonist peptide of the glucagonreceptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-likepeptide-1receptor (GLP-1R). Retatrutide binds human GCGR, GIPR, and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide can be used for the research of obesity .
Retatrutide (LY3437943) TFA is a triple agonist peptide of the glucagonreceptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-likepeptide-1receptor (GLP-1R). Retatrutide TFA binds human GCGR, GIPR, and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide TFA can be used for the research of obesity .
Retatrutide (LY3437943) acetate is a triple agonist peptide of the glucagonreceptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-likepeptide-1receptor (GLP-1R). Retatrutide acetate inhibits human GCGR, GIPR, and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide acetate can be used for the research of obesity .
Des His1, Glu8 Exendin-4 is a potent glucagon-likepeptide-1receptor (GLP-1-R) antagonist. Des His1, Glu8 Exendin-4 improves glucose homeostasis by regulating both insulin secretion and glucose production. Des His1, Glu8 Exendin-4 can be used for the research of type 2 diabetic and gastrointestinal .
Semaglutide, a long-acting GLP-1 analogue, is a glucagon-likepeptide-1(GLP-1)receptor agonist. Semaglutide has the potential for type 2 diabetes treatment.
Albiglutide fragment (GLP-1 (7-36) analog) TFA is an active fragment of Albiglutide (7-36) and a glucagon-likepeptide-1 (GLP-1) analog (a long-acting GLP-1receptor agonist). Albiglutide is produced by the fusion of DPP-4 resistant GLP-1 dimer with the human albumin gene. Moreover, Albiglutide fragment TFA significantly reduces glycosylated hemoglobin (A1C) and is used in type 2 diabetes (T2D) studies .
Albiglutide fragment (GLP-1 (7-36) analog) is an active fragment of Albiglutide (7-36) and a glucagon-likepeptide-1 (GLP-1) analog (a long-acting GLP-1receptor agonist). Albiglutide is produced by the fusion of DPP-4 resistant GLP-1 dimer with the human albumin gene. Moreover, Albiglutide fragment significantly reduces glycosylated hemoglobin (A1C) and is used in type 2 diabetes (T2D) studies .
Semaglutide TFA, a long-acting GLP-1 analogue, is a glucagon-likepeptide-1(GLP-1)receptor agonist. Semaglutide TFA has the potential for type 2 diabetes treatment.
Dapiglutide (ZP7570) is a long-acting glucagon-likepeptide-1receptor 1R (GLP-1R)/Glucagon-likepeptide-2 receptor (GLP-2R) dual agonist. Dapiglutide can be used for short bowel syndrome (SBS) research .
Liraglutide- 13C6, 15N (TFA)is the 13C and 15N labeledLiraglutide(HY-P0014). Liraglutide is a glucagon-likepeptide-1 (GLP-1) receptor agonist used clinically to treat type 2 diabetes mellitus .
Liraglutide- 13C5, 15N (tetraTFA)is the 13C and 15N labeledLiraglutide(HY-P0014) . Liraglutide is a glucagon-likepeptide-1 (GLP-1) receptor agonist used clinically to treat type 2 diabetes mellitus .
Tirzepatide hydrochloride (LY3298176 hydrochloride) is a glucose-dependent insulin nutritive polypeptide (GIP) and glucagon-likepeptide-1(GLP-1)receptor dual agonist. Tirzepatide hydrochloride has neuroprotective effects and can be used in the study of type 2 diabetes, diabetes-related neuropathy and obesity .
Tirzepatide (LY3298176) is a glucose-dependent insulin nutritive polypeptide (GIP) and glucagon-likepeptide-1(GLP-1)receptor dual agonist. Tirzepatide has neuroprotective effects and can be used in the study of type 2 diabetes, diabetes-related neuropathy and obesity .
Tirzepatide TFA (LY3298176 hydrochloride) is a glucose-dependent insulin nutritive polypeptide (GIP) and glucagon-likepeptide-1(GLP-1)receptor dual agonist. Tirzepatide TFA has neuroprotective effects and can be used in the study of type 2 diabetes, diabetes-related neuropathy and obesity .
Bamadutide (SAR425899) is a potent dual glucagon-likepeptide-1receptor/glucagonreceptor agonist. Bamadutide (SAR425899) improves postprandial glucose control by significantly enhancing β-cell function and slowing glucose absorption rate in vivo. Bamadutide (SAR425899)can be used for type 2 diabetes research .
Exendin-4 (3-39) is a peptide. Exendin-4 (3-39) is a truncated form of Exendin-4 (HY-13443) that lacks the first two amino acids. Exendin-4 is a potent Glucagon-likepeptide-1receptor (GLP-1r) agonist. Exendin-4 (3-39) and Exendin-4 can be used for the research of diabetic and hypothalamic-pituitary-adrenal (HPA) axis .
Taspoglutide is a long-acting glucagon-likepeptide 1 (GLP-1) receptor agonist developed for treatment of type 2 diabetes, with an EC50 value of 0.06 nM.
Ecnoglutide (XW003) is a long-acting, cAMP-biased glucagon-likepeptide 1(GLP-1) receptor agonist. Ecnoglutide can be used for research of T2DM and obesity .
GLP-1 moiety from Dulaglutide is a 31-amino acid fragment of Dulaglutide which is a glucagon-likepeptide 1receptor (GLP-1) agonist, extracted from patent US 20160369010 A1.
GLP-1(9-36)amide TFA is a major metabolite of glucagon-likepeptide-1-(7-36) amide formed by the enzyme dipeptidyl peptidase-4 (DPP-4). GLP-1(9-36)amide TFA acts as an antagonist to the human pancreatic GLP-1 receptor .
Mazdutide (IBI-362; LY-3305677) is a long-acting synthetic oxyntomodulin analog. Mazdutide is also a co-agonist of glucagon-likepeptide (GLP-1R) and glucagonreceptor (GCGR). Mazdutide binds human and mouse GCGR (Ki: 17.7 nM and 15.9 nM, respectively) and GLP-1R (Ki: 28.6 nM and 25.1 nM, respectively) and stimulates insulin secretion from mouse islets (EC50: 5.2 nM). Mazdutide is used in studies of obesity and type 2 diabetes (T2D) .
Mazdutide (IBI-362; LY-3305677) TFA is a long-acting synthetic oxyntomodulin analog. Mazdutide is also a co-agonist of glucagon-likepeptide (GLP-1R) and glucagonreceptor (GCGR). Mazdutide TFA binds human and mouse GCGR (Ki: 17.7 nM and 15.9 nM, respectively) and GLP-1R (Ki: 28.6 nM and 25.1 nM, respectively) and stimulates insulin secretion from mouse islets (EC50: 5.2 nM). Mazdutide TFA is used in studies of obesity and type 2 diabetes (T2D) .
Shanzhiside methy lester is isolated from lamiophlomis rotata. Shanzhiside methyl ester is a small molecule glucagon-likepeptide-1 (GLP-1) receptor agonist and has the ability to induce anti-allodynic tolerance .
GLP1R protein, a G-protein coupled receptor, binds to GLP-1, activating adenylyl cyclase and increasing intracellular cAMP levels. This interaction regulates insulin secretion and maintains glucose homeostasis. GLP1R can also form dimers with GIPR, suggesting complex regulatory mechanisms and interactions with other receptors. GLP1R Protein, Mouse (His-SUMO) is the recombinant mouse-derived GLP1R protein, expressed by E. coli , with N-6*His, N-SUMO labeled tag. The total length of GLP1R Protein, Mouse (His-SUMO) is 124 a.a., with molecular weight of ~30.4 kDa.
The GLP1R protein is a G protein-coupled receptor for glucagon-like peptide 1 (GLP-1), which upon ligand binding activates adenylyl cyclase and increases cAMP levels. This interaction critically regulates insulin secretion, affecting cellular responses and metabolic processes associated with GLP-1 signaling. GLP1R Protein, Human (HEK293, Fc) is the recombinant human-derived GLP1R protein, expressed by HEK293 , with C-hFc labeled tag. The total length of GLP1R Protein, Human (HEK293, Fc) is 122 a.a., with molecular weight of 50-70 kDa.
The GLP1R protein is a G protein-coupled receptor for glucagon-like peptide 1 (GLP-1), which upon ligand binding activates adenylyl cyclase and increases cAMP levels. This interaction critically regulates insulin secretion, affecting cellular responses and metabolic processes associated with GLP-1 signaling. GLP1R Protein, Human (HEK293, N-His, C-Myc) is the recombinant human-derived GLP1R protein, expressed by HEK293 , with C-Myc, N-10*His labeled tag. The total length of GLP1R Protein, Human (HEK293, N-His, C-Myc) is 122 a.a., with molecular weight of 33 kDa.
Liraglutide- 13C6, 15N (TFA)is the 13C and 15N labeledLiraglutide(HY-P0014). Liraglutide is a glucagon-likepeptide-1 (GLP-1) receptor agonist used clinically to treat type 2 diabetes mellitus .
Liraglutide- 13C5, 15N (tetraTFA)is the 13C and 15N labeledLiraglutide(HY-P0014) . Liraglutide is a glucagon-likepeptide-1 (GLP-1) receptor agonist used clinically to treat type 2 diabetes mellitus .
GLP-1R Antibody is an unconjugated, approximately 51 kDa, rabbit-derived, anti-GLP-1R polyclonal antibody. GLP-1R Antibody can be used for: WB, ELISA, IHC-P, IHC-F, Flow-Cyt, ICC, IF expriments in human, mouse, rat, and predicted: dog background without labeling.
Inquiry Online
Your information is safe with us. * Required Fields.